Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Arch. endocrinol. metab. (Online) ; 62(6): 597-601, Dec. 2018. tab
Artigo em Inglês | LILACS | ID: biblio-983809

RESUMO

ABSTRACT Objectives: This study aims to verify the new-onset diabetes after kidney transplant (NODAT) incidence in recipients within 1 year after kidney transplantation from a single center in Southern Brazil and to assess the associated conditions. Subjects and methods: A retrospective study of 258 post-renal transplant patients was performed. Demographic (gender, age, ethnic background) and clinical (origin of graft, associated infections, body mass index (BMI) at transplant time and 6 and 12 months after, causes of renal failure, and comorbidities) data were analyzed. All patients were on tacrolimus, mycophenolate mofetil, and prednisone treatment. Patients with and without NODAT were compared. Results: A NODAT incidence of 31.2% was noted 1 year post transplantation. In the univariate analysis, patients with NODAT were older (p = 0.001), mostly had African-American ethnic background (p = 0.02), and had renal failure secondary to high blood pressure (HBP) (p = 0.001). The group of patients with NODAT also had more incidence of post-transplant HBP (p = 0.01), heart failure (p = 0.02), and dyslipidemia (p = 0.001). Logistic regression showed that African-American ethnic background, post-transplant HBP, and dyslipidemia were independently associated with NODAT. Conclusion: This study shows a NODAT incidence that is greater in patients with African-American ethnic background and that is associated with HBP and dyslipidemia.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Transplante de Rim/efeitos adversos , Diabetes Mellitus/etiologia , Complicações Pós-Operatórias/epidemiologia , Brasil/epidemiologia , Modelos Logísticos , Incidência , Estudos Retrospectivos , Fatores de Risco , Tacrolimo/efeitos adversos , Estatísticas não Paramétricas , Diabetes Mellitus/epidemiologia , Dislipidemias/etiologia , Hipertensão/etiologia , Imunossupressores/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA